Combinations comprising lanifibranor and a GLP-1 / GIP / glucagon triple receptor agonist for use in the treatment of liver diseases

A combination of lanifibranor and a GLP-1/GIP/glucagon triple receptor agonist addresses the lack of treatments for NAFLD and NASH by reducing liver fat, inflammation, and fibrosis, offering a therapeutic option for these conditions.

WO2026125286A1 Publication Date: 2026-06-18INVENTIVA
0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
INVENTIVA
Filing Date
2025-12-08
Publication Date
2026-06-18

AI Technical Summary

⚠Technical Problem

There is no approved treatment for non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH), which can lead to severe complications such as fibrosis, cirrhosis, liver cancer, and cardiovascular disease, and current therapies do not effectively address these conditions.

⚗Method used

A combination therapy using lanifibranor, a pan-PPAR agonist, and a GLP-1/GIP/glucagon triple receptor agonist is administered to treat liver diseases, including NAFLD and NASH, targeting multiple mechanisms of action to improve liver health.

🎯Benefits of technology

The combination therapy effectively reduces liver fat accumulation, inflammation, and fibrosis, providing a potential treatment for NAFLD and NASH, potentially preventing progression to more severe conditions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The present disclosure relates to a drug combination and a method for the prevention and / or the treatment of a liver disease, the combination comprising lanifibranor or a deuterated form thereof and a GLP-1 / GIP / glucagon triple receptor agonist.
Need to check novelty before this filing date? Find Prior Art